← Back to Search

Other

Ringer's lactate for Diabetic Ketoacidosis (BRISK-ED Trial)

N/A
Waitlist Available
Led By Justin W Yan, MD, MSc
Research Sponsored by Lawson Health Research Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up one year
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing whether Ringer's Lactate, a type of IV fluid, can help adults with diabetic ketoacidosis (DKA) recover faster than the commonly used normal saline. Ringer's Lactate is thought to be more balanced and less likely to increase blood acidity. If successful, this could lead to shorter hospital stays and better outcomes for patients. Ringer's Lactate has been studied as an alternative to normal saline for various conditions, including diabetic ketoacidosis, due to its balanced electrolyte composition and lower risk of causing acidosis.

Eligible Conditions
  • Diabetic Ketoacidosis

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~one year
This trial's timeline: 3 weeks for screening, Varies for treatment, and one year for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Patient recruitment rate (feasibility outcome)
Time to DKA resolution (efficacy outcome)
Secondary study objectives
Hospital length of stay
Hyper- or hypo-kalemia post-emergency department
In-hospital acute kidney injury (Stage 2 or greater) post-emergency department
+4 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Ringer's lactateExperimental Treatment1 Intervention
The intervention is administration of IV Ringer's lactate. Rate of study fluid will be at the treating physician's (both ED and inpatient, if consulted for admission) discretion. Apart from fluid administered, there will be no other changes to the patient's clinical care, and patients will receive standard DKA treatment which may include insulin, electrolyte replacement, and/or supportive management. Pharmacy-prepared kits of 8 x 1L bags of study fluid (in Self et al., a maximum of 7090mL was given8) will be kept in a secure space within the ED. Once packaged, IV bags are useable for 30 days before expiration. If a kit is opened but not used completely, individual 1L bags may be returned to the pharmacy to save on costs.
Group II: Normal salineActive Control1 Intervention
The comparator is administration of IV normal saline. Rate of study fluid will be at the treating physician's (both ED and inpatient, if consulted for admission) discretion. Apart from fluid administered, there will be no other changes to the patient's clinical care, and patients will receive standard DKA treatment which may include insulin, electrolyte replacement, and/or supportive management. Pharmacy-prepared kits of 8 x 1L bags of study fluid (in Self et al., a maximum of 7090mL was given8) will be kept in a secure space within the ED. Once packaged, IV bags are useable for 30 days before expiration. If a kit is opened but not used completely, individual 1L bags may be returned to the pharmacy to save on costs.

Find a Location

Who is running the clinical trial?

Lawson Health Research InstituteLead Sponsor
676 Previous Clinical Trials
416,591 Total Patients Enrolled
Justin W Yan, MD, MScPrincipal InvestigatorLawson Health Research Institute/Western University
~13 spots leftby Oct 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top